US Patent

US11426373 — Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Method of Use · Assigned to Jazz Pharmaceuticals Ireland Ltd · Expires 2037-09-19 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions and formulations of mixed salts of gamma-hydroxybutyrate for treating various sleep disorders.

USPTO Abstract

Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3432`	—

Patent Metadata

Patent number: US11426373
Jurisdiction: US
Classification: Method of Use
Expires: 2037-09-19
Drug substance claim: No
Drug product claim: No
Assignee: Jazz Pharmaceuticals Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.